Testosterone to Dihydrotestosterone Ratio as a New Biomarker for an Adverse Metabolic Phenotype in the Polycystic Ovary Syndrome

被引:85
作者
Muenzker, J. [1 ]
Hofer, D. [1 ]
Trummer, C. [1 ]
Ulbing, M. [1 ]
Harger, A. [1 ]
Pieber, T. [1 ]
Owen, L. [2 ]
Keevil, B. [2 ]
Brabant, G. [3 ,4 ]
Lerchbaum, E. [1 ]
Obermayer-Pietsch, B. [1 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Metab, A-8036 Graz, Austria
[2] Univ S Manchester Hosp, Manchester Acad Hlth Sci Ctr, Dept Clin Chem, Manchester M23 9LT, Lancs, England
[3] Univ Manchester, The Christie, Dept Endocrinol, Manchester M20 4BX, Lancs, England
[4] Med Univ Lubeck, Expt & Clin Endocrinol, Med Clin 1, D-23538 Lubeck, Germany
基金
奥地利科学基金会;
关键词
SERUM TESTOSTERONE; MASS-SPECTROMETRY; SYNDROME PCOS; WOMEN; RISK; HYPERANDROGENEMIA; IMMUNOASSAY; ENDOCRINE; OBESITY; UTILITY;
D O I
10.1210/jc.2014-2523
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Polycystic ovary syndrome (PCOS) is a heterogeneous disease with many different aspects, including hyperandrogenism and metabolic disturbances. Clinical phenotypes show different patterns of steroid hormones that have been investigated to some extent. Objective: This study intended to determine the role of the testosterone (TT) to dihydrotestosterone (DHT) ratio (TT/DHT ratio) in PCOS patients and to further assess the correlation of this ratio with hormonal, anthropometric, and metabolic parameters. Design and Setting: Serum samples of 275 premenopausal PCOS patients fulfilling Rotterdam criteria and 35 BMI-matched, premenopausal, healthy controls were analyzed for testosterone, DHT, dehydroepiandrosterone (DHEA), and androstenedione using liquid chromatography/mass spectrometry. Main Outcome Measures: We measured total levels of testosterone and DHT and calculated un-bound hormone levels as well as the ratio of testosterone to DHT. Further, impaired glucose tolerance, basal and stimulated serum insulin levels, metabolic syndrome and insulin resistance according to the homeostatic model assessment (HOMA-IR) were assessed. Results: PCOS patients showed significantly higher levels of TT (P < .001), free testosterone (P < .001), and freeDHT(P < .001) compared to healthy controls. The TT/DHT ratio was significantly higher in PCOS patients (P < .001). No difference was found for total DHT levels (P < .072). In PCOS patients alone, the TT/DHT ratio was significantly higher in obese patients (P < .001) and patients with metabolic syndrome (P < .001), impaired glucose tolerance (IGT) (P < .001) or insulin resistance (P < .001). Significant correlations of the TT/DHT ratio with various adverse anthropometric, hormonal, lipid and liver parameters and parameters of glucose metabolism were found. Conclusion: Our data provide evidence for a strong link between a high TT/DHT ratio and an adverse metabolic phenotype in PCOS patients. This correlation was only found in PCOS patients, suggesting the TT/DHT ratio to be a new biomarker for an adverse metabolic phenotype in PCOS patients.
引用
收藏
页码:653 / 660
页数:8
相关论文
共 50 条
[41]   Metabolic Dysfunction-Associated Steatotic Liver Disease and Polycystic Ovary Syndrome: A Complex Interplay [J].
Arvanitakis, Konstantinos ;
Chatzikalil, Elena ;
Kalopitas, Georgios ;
Patoulias, Dimitrios ;
Popovic, Djordje S. ;
Metallidis, Symeon ;
Kotsa, Kalliopi ;
Germanidis, Georgios ;
Koufakis, Theocharis .
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)
[42]   The phenotype of polycystic ovary syndrome ameliorates with aging [J].
Brown, Zoe A. ;
Louwers, Yvonne V. ;
Fong, Sharon Lie ;
Valkenburg, Olivier ;
Birnie, Erwin ;
de Jong, Frank H. ;
Fauser, Bart C. J. M. ;
Laven, Joop S. E. .
FERTILITY AND STERILITY, 2011, 96 (05) :1259-1265
[43]   What Is the Male Polycystic Ovary Syndrome Phenotype? [J].
Welt, Corrine K. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (05) :E2188-E2189
[44]   The relationships of sex hormone-binding globulin, total testosterone, androstenedione and free testosterone with metabolic and reproductive features of polycystic ovary syndrome [J].
Simons, Pomme I. H. G. ;
Valkenburg, Olivier ;
Bons, Judith A. P. ;
Stehouwer, Coen D. A. ;
Brouwers, Martijn C. G. J. .
ENDOCRINOLOGY DIABETES & METABOLISM, 2021, 4 (03)
[45]   The prevalence of metabolic syndrome in clomiphene citrate resistant polycystic ovary syndrome [J].
Verit, Fatma Ferda .
GYNECOLOGICAL ENDOCRINOLOGY, 2012, 28 (05) :365-369
[46]   Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome [J].
Krentowska, Anna ;
Kowalska, Irina .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2022, 38 (01)
[47]   Impact of Autoimmune Thyroiditis on Reproductive and Metabolic Parameters in Patients with Polycystic Ovary Syndrome [J].
Ulrich, Jan ;
Goerges, Julia ;
Keck, Christoph ;
Mueller-Wieland, Dirk ;
Diederich, Sven ;
Janssen, Onno Eilard .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2018, 126 (04) :198-204
[48]   Chemerin and Polycystic Ovary Syndrome: A Comprehensive Review of Its Role as a Biomarker and Therapeutic Target [J].
Palomba, Stefano ;
Seminara, Giuseppe ;
Costanzi, Flavia ;
Caserta, Donatella ;
Aversa, Antonio .
BIOMEDICINES, 2024, 12 (12)
[49]   Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria [J].
Yildiz, Bulent Okan ;
Bozdag, Gurkan ;
Yapici, Zuhal ;
Esinler, Ibrahim ;
Yarali, Hakan .
HUMAN REPRODUCTION, 2012, 27 (10) :3067-3073
[50]   Insulin Resistant Phenotype of Polycystic Ovary Syndrome does not Seem to be Caused by Variation in FTO [J].
Hatziagelaki, E. ;
Wagner, R. ;
Kantartzis, K. ;
Heni, M. ;
Linder, K. ;
Ketterer, C. ;
Machicao, F. ;
Stefan, N. ;
Staiger, H. ;
Haering, H. U. ;
Fritsche, A. .
HORMONE AND METABOLIC RESEARCH, 2012, 44 (11) :810-813